NO20071570L - Fremstilling av TNFR-Ig fusjonsprotein - Google Patents

Fremstilling av TNFR-Ig fusjonsprotein

Info

Publication number
NO20071570L
NO20071570L NO20071570A NO20071570A NO20071570L NO 20071570 L NO20071570 L NO 20071570L NO 20071570 A NO20071570 A NO 20071570A NO 20071570 A NO20071570 A NO 20071570A NO 20071570 L NO20071570 L NO 20071570L
Authority
NO
Norway
Prior art keywords
cumulative
culture
amino acid
glutamine
molar
Prior art date
Application number
NO20071570A
Other languages
English (en)
Other versions
NO344785B1 (no
Inventor
Denis Drapeau
Yen-Tuang Luan
James R Mercer
Wenge Wang
Daniel Lasko
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071570(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of NO20071570L publication Critical patent/NO20071570L/no
Publication of NO344785B1 publication Critical patent/NO344785B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Et forbedret system for storskala-produksjon av et dimert fusjonsprotein bestående av den ekstracellulære ligand-bindende del av human (p75) tumornekrosefaktor-reseptor (TNFR) bundet til Fc-delen av IgGI i cellekultur, spesielt i media karakterisert ved én eller flere av: i) en kumulativ aminosyre-konsentrasjon større enn ca. 70 mM; ii) et molart kumulativ glutamin til kumulativ asparagin forhold på mindre enn ca. 2; iii) et molart kumulativ glutamin til kumulativ total aminosyre forhold på mindre enn ca. 0,2; iv) et molart kumulativt uorganisk ion til kumulativ total aminosyre forhold mellom ca. 0,4 til 1; eller v) en kombinert kumulativ glutamin- og kumulativ asparagin-konsentrasjon mellom ca. 16 og 36 mM er gitt. Anvendelse av et slikt system tillater høye nivåer av protein-produksjon og minker akkumulering av visse uønskede faktorer så som ammonium og/eller laktat. I tillegg er kulturmetoder omfattende et temperaturskift, typisk omfattende en reduksjon av temperatur når kulturen har nådd ca. 20-80% av den maksimale celletetthet, gitt. Alternativt eller i tillegg tilveiebringer foreliggende oppfinnelse metoder slik at, etter å ha nådd en topp, laktat- og/eller ammonium-nivåer i kulturen reduseres over tid.
NO20071570A 2004-08-27 2007-03-26 Metode for å produsere TNFR-Ig i en storskala-produksjon cellekultur. NO344785B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27
PCT/US2005/030439 WO2006026447A2 (en) 2004-08-27 2005-08-26 PRODUCTION OF TNFR-Ig FUSION PROTEIN

Publications (2)

Publication Number Publication Date
NO20071570L true NO20071570L (no) 2007-05-23
NO344785B1 NO344785B1 (no) 2020-04-27

Family

ID=35500648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071570A NO344785B1 (no) 2004-08-27 2007-03-26 Metode for å produsere TNFR-Ig i en storskala-produksjon cellekultur.

Country Status (38)

Country Link
US (1) US7300773B2 (no)
EP (2) EP1781802B1 (no)
JP (3) JP2008511330A (no)
KR (1) KR100988451B1 (no)
CN (2) CN102876761A (no)
AR (2) AR050537A1 (no)
AT (2) ATE446376T1 (no)
AU (1) AU2005280036B2 (no)
BR (1) BRPI0514694B8 (no)
CA (1) CA2578138C (no)
CL (1) CL2017000577A1 (no)
CR (2) CR8998A (no)
CY (2) CY1109721T1 (no)
DE (2) DE602005020076D1 (no)
DK (2) DK1781802T3 (no)
EC (1) ECSP077354A (no)
EG (1) EG26922A (no)
ES (2) ES2335518T3 (no)
GT (2) GT200500234A (no)
HK (2) HK1099941A1 (no)
HN (1) HN2005000485A (no)
HR (2) HRP20100011T1 (no)
IL (1) IL181588A (no)
MX (1) MX2007002381A (no)
MY (1) MY137803A (no)
NO (1) NO344785B1 (no)
NZ (1) NZ579208A (no)
PE (2) PE20100448A1 (no)
PL (2) PL1781802T3 (no)
PT (2) PT1781802E (no)
RS (2) RS51255B (no)
RU (1) RU2458988C2 (no)
SI (2) SI1992697T1 (no)
SV (1) SV2006002211A (no)
TW (1) TWI364458B (no)
UA (1) UA89383C2 (no)
WO (1) WO2006026447A2 (no)
ZA (1) ZA200701672B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
DK3255141T3 (da) * 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
WO2008055260A2 (en) * 2006-11-03 2008-05-08 Wyeth Glycolysis-inhibiting substances in cell culture
TW200827445A (en) * 2006-11-08 2008-07-01 Wyeth Corp Rationally designed media for cell culture
PT2115126E (pt) 2007-03-02 2015-08-24 Wyeth Llc Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TWI601823B (zh) 2007-04-26 2017-10-11 Chugai Pharmaceutical Co Ltd Cell culture methods using media containing high concentrations of amino acids
JP5739324B2 (ja) * 2008-04-17 2015-06-24 ワイス・エルエルシー 骨形成タンパク質の産生増進法
JP2011516086A (ja) * 2008-04-18 2011-05-26 上海中信国健薬業股▲ふん▼有限公司 濃縮培養液及びその使用方法
WO2010016943A2 (en) * 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
RU2639288C2 (ru) 2009-08-11 2017-12-20 Дженентек, Инк. Получение белков в культуральных средах без глутамина
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
RU2577972C2 (ru) 2010-04-26 2016-03-20 Новартис Аг Способ получения рекомбинантного полипептида
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2014503495A (ja) * 2010-11-15 2014-02-13 バイオジェン アイデック インコーポレイテッド 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮
DK2702164T3 (en) 2011-04-29 2016-02-01 Biocon Res Ltd METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
AU2012326171B2 (en) 2011-10-18 2017-03-09 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AU2012324495B2 (en) 2011-10-21 2016-04-21 Pfizer Inc. Addition of iron to improve cell culture
NZ629309A (en) * 2012-02-22 2016-03-31 Nvip Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG10201802023RA (en) 2013-03-26 2018-05-30 Coherus Biosciences Inc Protein production method
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
CN105637085A (zh) * 2013-10-11 2016-06-01 瑞泽恩制药公司 代谢优化的细胞培养物
MX362923B (es) 2014-01-30 2019-02-25 Coherus Biosciences Inc Medios de perfusión.
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
EA036178B1 (ru) 2014-12-01 2020-10-09 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе гликопротеинов
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
CN114807010A (zh) * 2015-04-01 2022-07-29 勃林格殷格翰国际公司 细胞培养基
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
US20240083972A1 (en) 2020-12-22 2024-03-14 Amgen Inc. Cell culture method
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU632065B2 (en) * 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
DE69032483T2 (de) * 1989-10-05 1998-11-26 Optein, Inc., Seattle, Wash. Zellfreie synthese und isolierung von genen und polypeptiden
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
EP1385545B1 (en) 2001-04-30 2009-01-07 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
US7320790B2 (en) 2001-04-30 2008-01-22 Eli Lilly And Company Humanized antibodies
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP4429728B2 (ja) 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
AU2003217612A1 (en) 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides

Also Published As

Publication number Publication date
HN2005000485A (es) 2009-06-09
NO344785B1 (no) 2020-04-27
DE602005020076D1 (de) 2010-04-29
TWI364458B (en) 2012-05-21
BRPI0514694B1 (pt) 2019-04-24
CA2578138C (en) 2010-10-05
CL2017000577A1 (es) 2017-12-01
SI1992697T1 (sl) 2010-07-30
MY137803A (en) 2009-03-31
WO2006026447A2 (en) 2006-03-09
HRP20100011T1 (hr) 2010-02-28
RU2458988C2 (ru) 2012-08-20
HRP20100271T1 (hr) 2010-06-30
IL181588A0 (en) 2007-07-04
JP2008511330A (ja) 2008-04-17
PE20100448A1 (es) 2010-06-22
US7300773B2 (en) 2007-11-27
RS51072B (sr) 2010-10-31
AU2005280036B2 (en) 2011-11-03
PT1992697E (pt) 2010-04-21
WO2006026447A9 (en) 2006-06-01
AR050537A1 (es) 2006-11-01
RS51255B (sr) 2010-12-31
NZ579208A (en) 2012-01-12
CY1110092T1 (el) 2015-01-14
CR8998A (es) 2007-11-23
PL1992697T3 (pl) 2010-08-31
ES2341390T3 (es) 2010-06-18
EP1992697A1 (en) 2008-11-19
CA2578138A1 (en) 2006-03-09
HK1121497A1 (en) 2009-04-24
EG26922A (en) 2014-12-25
PE20060815A1 (es) 2006-09-14
CN101061231A (zh) 2007-10-24
CY1109721T1 (el) 2014-08-13
PT1781802E (pt) 2010-01-04
CR20120560A (es) 2012-12-04
JP5921910B2 (ja) 2016-05-24
JP2012095672A (ja) 2012-05-24
ATE461285T1 (de) 2010-04-15
ECSP077354A (es) 2007-05-30
UA89383C2 (ru) 2010-01-25
TW200619388A (en) 2006-06-16
EP1781802B1 (en) 2009-10-21
KR20070069140A (ko) 2007-07-02
WO2006026447A3 (en) 2006-04-20
AU2005280036A1 (en) 2006-03-09
AR088824A2 (es) 2014-07-10
SV2006002211A (es) 2006-10-04
EP1992697B1 (en) 2010-03-17
SI1781802T1 (sl) 2010-01-29
US20060121569A1 (en) 2006-06-08
EP1781802A2 (en) 2007-05-09
MX2007002381A (es) 2007-06-15
CN101061231B (zh) 2012-09-26
DK1781802T3 (da) 2010-01-25
CN102876761A (zh) 2013-01-16
HK1099941A1 (en) 2007-08-31
BRPI0514694B8 (pt) 2021-05-25
DK1992697T3 (da) 2010-05-17
RU2007108717A (ru) 2008-10-10
GT200500234A (es) 2006-10-10
ZA200701672B (en) 2012-04-24
ES2335518T3 (es) 2010-03-29
PL1781802T3 (pl) 2010-03-31
ATE446376T1 (de) 2009-11-15
DE602005017285D1 (no) 2009-12-03
JP2016056214A (ja) 2016-04-21
GT200500233A (es) 2006-03-09
BRPI0514694A (pt) 2008-06-17
KR100988451B1 (ko) 2010-10-18
IL181588A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
NO20071570L (no) Fremstilling av TNFR-Ig fusjonsprotein
NO20071572L (no) Fremstilling av polypeptider
MX2007002382A (es) Producci??n de anticuerpos anti-amiloides beta.
IL292650B2 (en) IL13RA2-targeted chimeric antigen receptor T cells
BR112017013189B1 (pt) Agentes agonísticos de ligação ao receptor de tnf
CN107208069A (zh) 用于表达免疫检查点调节因子的溶瘤病毒
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
KR20200044138A (ko) 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
RU2010120677A (ru) Клетка для получения гетеропротеинов и способ получения на ее основе
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
JP2020512284A5 (no)
MX2020012499A (es) Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh.
EP2530090A3 (en) Anti-IL-13R alpha 1 antibodies and their uses thereof
EP2124522A4 (en) PUTATIVE RECEPTOR OF CYTOKININ AND METHODS OF USE
RU2009117253A (ru) Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании
CA2538863A1 (en) Selection system containing non-antibiotic resistance selection marker
Wang et al. The cloning and expression of renalase and the preparation of its monoclonal antibody
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
AU2013251375B2 (en) Vascular endothelial growth factor antagonists and methods for their use
CN103421749B (zh) 棉花多胺氧化酶GhPAO2基因及其应用
WO2010005227A3 (ko) 동물세포용 재조합 발현벡터
CA3200980A1 (en) Cytosolic protein targeting engineered deubiquitinases and methods of use thereof
Usami et al. GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NEW SUSCEPTIBILITY LOCI FOR UROLITHIASIS
Khandrika et al. IN VIVO ACTIVATION OF P38 MITOGEN ACTIVATED PROTEIN KINASE SIGNALING CASCADE IN A HYPEROXALURIC RAT MODEL

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PFIZER IRELAND PHARMACEUTICALS

MM1K Lapsed by not paying the annual fees